Key result
This review discusses the hypothesis and available data suggesting that lipid-lowering drugs may reduce life-threatening ventricular arrhythmias in patients with coronary artery disease.
Why the study?
Do lipid-lowering drugs reduce life-threatening ventricular arrhythmias in patients with coronary artery disease?
Do lipid-lowering drugs reduce life-threatening ventricular arrhythmias in patients with coronary artery disease?
This review highlights the potential role of lipid-lowering drugs in reducing life-threatening ventricular arrhythmias in patients with coronary artery disease by mitigating myocardial ischemia.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for lipid-lowering reducing ventricular arrhythmias in CAD; prospective RCTs needed before practice change.
Ventricular arrhythmias are the most common cause of sudden cardiac death in patients with coronary artery disease. Since treatment of hypercholesterolemia in patients with coronary artery disease reduces the risk of major coronary events by about 30%, one could speculate that this treatment could also result in a reduction of arrhythmic episodes in high-risk patients. In this review, the importance of myocardial ischemia as a trigger for ventricular arrhythmias, as well as the available data that suggest a possible effect of anti-ischemic treatments, including lipid-lowering drugs, on these arrhythmias are presented. Also, possible mechanisms and future research to test the hypothesis that lipid-lowering drugs can reduce life-threatening ventricular arrhythmias are discussed.
No takes yet. Share an insight, caveat, or question.
Sutter et al. (2002) conducted a review in Coronary artery disease. Lipid-lowering drugs was evaluated. This review discusses the hypothesis and available data suggesting that lipid-lowering drugs may reduce life-threatening ventricular arrhythmias in patients with coronary artery disease.
Synapse has enriched 10 related papers. Consider them for comparative context: